The results of the corona vaccine are quite impressive, know how long you will get the vaccine

new Delhi: Coronavirus As the trial of the vaccine is progressing at a rapid pace, the expectation of an approved vaccine becoming available in the Indian market by early 2021 is increasing. Bernstein said this in a report.

Fast work is being done on four vaccines
Currently, there are four potential vaccines globally, which are expected to be approved by the end of 2020 or early 2021. Two of these have been partnered by India for the vaccine 'AstraZeneca and Oxford's viral vector vaccine' and 'Novavax's protein subunit vaccine'.

According to the report, “Phase I and Phase II trials for both these vaccines enhance safety and immunity response seems reliable. We are optimistic that an approved vaccine will be available in the market in the first quarter of 2021 in India. '

Vaccine price
Bernstein said the cost of the vaccine could be three to six dollars (225 to 550 rupees) per dose, and collective immunity could take up to two years to develop due to implementation difficulties. The reason for this is the lack of experience in mass vaccination.

Also read- careful! Fake notices in the name of ED are being sent to these states, know what is the matter

According to the report, India has two experiences of large-scale vaccination. One was the Polia Eradication Campaign of 2011 and the other the recent Intensive Mission Indradhanush (IMI), but their level was one-third of the level required for the Kovid-19.

India will face challenges
Bernstein said that the number of cold stores and lack of skilled labor are two major challenges. Even if we assume that the speed of implementation will be twice as much as before, it will still take 18 to 20 months to implement the government program.

He said, 'We believe that initially the vaccine will be made available to sensitive groups like health workers and people above 65 years of age etc. After this, the vaccine can be given to people engaged in essential services and to the economically poor. '

According to the report, Novavax's vaccine is giving better results than AstraZeneca and Oxford. Both have given good results in the first two phases and are now in the third phase. For this, a person will need to give two doses in an interval of 21 to 28 days.

India able to make one billion doses of vaccine
Bernstein said that the Serum Institute of India is fully ready to introduce the vaccine first. The Serum Institute has tied up with AstraZeneca and both Oxford and Novavax to produce their potential vaccines. It has the ability to produce both a protein sub unit and a viral vector vaccine. If required, the ability of both types can be increased by changing one. We do not see any hindrance on the manufacturing front.

He said, 'Serum Institute is also working on an additional capacity of one billion doses. We estimate that they will be able to produce 60 crore doses in 2021 and one billion doses in 2022. Of these, 40 to 50 crore doses will be available for India in 2021. '

Apart from this, three companies of India, Zydus, Bharat Biotech and Biological e are also working on their own vaccines. These vaccines are in Phase I and Phase II trials.

VIDEO

पूरा पढ़ें